New tissue repair strategies

Pressure Ulcer Research: Current and Future Perspectives

Volumn , Issue , 2005, Pages 353-374

  Bronneberg, Debbie ^a   Bouten, Carlijn ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33646420464     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/3-540-28804-X_20     Document Type: Chapter

References (110)

1. American Pressure Ulcer Advisory Panel (1998) Pressure ulcers prevalence, cost and risk assessment: consensus development conference statement. Decubitus 2:24-28
2. Brem H, Lyder CH (2004) Protocol for the successful treatment of pressure ulcers. Am J Surg 188 [Suppl 1A]: 9-17
3. Bouten CVC, Oomens CWJ, Baaijens FPT, Bader DL (2003) The etiology of pressure ulcers: skin deep or muscle bound? Arch Phys Med Rehabil 84:616-619
4. Barrois B, Allaert FA, Colin DA (1995) A survey of pressure sore prevalence in hospitals in the greater Paris region. J Wound Care 4:234-236
5. Baumgarten M, Margolis D, Berlin JA, Strom BL, Garino J, Kagan SH, Kavesh W, Carson JL (2003) Risk factors for pressure ulcers among early hip fracture patients. Wound Repair Regen 11:96-103
6. Pearson A, Francis K, Hodgkinson B, Curry G (2000) Prevalence and treatment of pressure ulcers in northern New South Wales. Aust J Rural Health 8:103-110
7. Meehan M (1990) Multisite pressure ulcer prevalence survey. Decubitus 3:14-17
8. Bours GJ, Halfens RJ, Lubbers M, Haalboom JR (1999) The development of a national registration form to measure the prevalence of pressure ulcers in The Netherlands. Ostomy Wound Manage 45:28-33, 36-38, 40
9. Allman RM, Laprade CA, Noel LB, et al. (1986) Pressure sores among hospitalized patients. Ann Intern Med 105:337-342
10. Brandeis GH, Morris JN, Nash DJ, Lipsitz LA (1990) The epidemiology and natural history of pressure ulcers in elderly nursing home residents. JAMA 264:2905-2909
11. Walter JS, Sacks J, Othman R, et al. (2002) A database of self-reported secondary medical problems among VA spinal cord injury patients: its role in clinical care and management. J Rehabil Res Dev 39:53-61
12. Garber SL, Rintala DH (2003) Pressure ulcers in veterans with spinal cord injury: a retrospective study. J Rehabil Res Dev 40:433-441
13. Jeffcoate WJ, Price P, Harding KG (2004) Wound healing and treatments for people with diabetic foot ulcers. Diabetes Metab Res Rev 20:S78-S89
14. Calvin M (1998) Cutaneous wounds repair. Wounds 10:12-32
15. Martin P (1997) Wound healing - aiming at the perfect skin regeneration. Science 276:75-81
16. Hunt TK, Hopf H, Hussain Z (2000) Physiology of wound healing. Adv Skin Wound Care 13 [Suppl2]: 6-11
17. Witte MB, Barbul A (1997) General principles of wound healing. Surg Clin North Am 77:509-528
18. Hunt TK, Zabel DD (1995) Critical care of wounds and wounded patients. In: Ayres SM, Grenvik A, Holbrook PR, et al (eds) Textbook of critical care, 3rd edn. Saunders, Philadelphia, pp 1457-1486
19. Hubner G, Brauchle M, Smola H, Madlener M, Fassler R, Werner S (1996) Differential regulation of pro-inflammatory cytokines during wound healing in normal and glucocorticoid-treated mice. Cytokine 8:548-556
20. Leibovich SJ, Ross R (1975) The role of the macrophage in wound repair. A study with hydrocortisone and antimacrophage serum. Am J Pathol 78:71-100
21. Risau W (1997) Mechanisms of angiogenesis. Nature 386:671-674
22. Stephens P, Thomas DW (2002) The cellular proliferative phase of the wound repair process. J Wound Care 11:253-261
23. Gipson IK, Spurr-Michaud SJ, Tisdale AS (1988) Hemidesmosomes and anchoring fibril collagen appear synchronously during development and wound healing. Dev Biol 126:253-262
24. Feng JJ, Hussain MZ, Constant J, et al. (1998) Angiogenesis in wound healing. J Surg Pathol 3:1-8
25. Diegelmann RF, Evans MC (2004) Wound healing: an overview of acute, fibrotic and delayed healing. Front Biosci 9:283-289
26. Payne WG, Ochs DE, Meltzer DD, et al. (2001) Long-term outcome study of growth factor-treated pressure ulcers. Am J Surg 181:81-86
27. Mast BA, Schultz GS (1996) Interactions of cytokines, growth factors, and proteases in acute and chronic wounds. Wound Repair Regen 4:411-420
28. Tarnuzzer RW, Macauley SP, Mast BA, et al. (1997) Epidermal growth factor in wound healing: a model for the molecular pathogenesis of chronic wounds. In: Ziegler T, Pierce G, Herndon D, editors. Growth factors and wound healing. Springer, New York Berlin Heidelberg, pp 206-228
29. Robson MC, Hill DP, Smith PD, Wang X, Meyer-Siegler K, Ko F, Vande Berg JS, Payne WG, Ochs D, Robson LE (2000) Sequential cytokine therapy for pressure ulcers: clinical and mechanistic response. Ann Surg 231:600-611
30. Cooper DM, Yu EZ, Hennessey P, Ko F, Robson MC (1994) Determination of endogenous cytokines in chronic wounds. Ann Surg 219:688-691
31. Nwomeh BC, Liang HX, Diegelmann RF, Cohen IK, Yager DR (1998) Dynamics of the matrix metalloproteinases MMP-1 and MMP-8 in acute open human dermal wounds. Wound Repair Regen 6:127-134
32. Nwomeh BC, Liang HX, Cohen IK, Yager DR (1999) MMP-8 is the predominant collagenase in healing wounds and nonhealing ulcers. J Surg Res 81:189-195
33. Yager DR, Zhang LY, Liang HX, Diegelmann RF, Cohen IK (1996) Wound fluids from human pressure ulcers contain elevated matrix metalloproteinase levels and activity compared to surgical wound fluids. J Invest Dermatol 107:743-748
34. Wenk J, Foitzik A, Achterberg V, Sabiwalsky A, Dissemond J, Meewes C, Reitz A, Brenneisen P, Wlaschek M, Meyer-Ingold W, Scharffetter-Kochanek K (2001) Selective pick-up of increased iron by deferoxamine-coupled cellulose abrogates the iron-driven induction of matrix-degrading metalloproteinase 1 and lipid peroxidation in human dermal fibroblasts in vitro: a new dressing concept. J Invest Dermatol 116:833-839
35. Eaglstein WH, Falanga V (1997) Chronic wounds. Surg Clin North Am 77:689-700
36. Ehrlich HP, Diegelmann RF (1994) Responses from the wound healing clinical focus group at the Food and Drug Administration to the Government Relations Committee of the Wound Healing Society. Stars and Stripes Newsletter of the Wound Healing Society 4:5-12
37. Margolis DJ, Lewis VL (1995) A literature assessment of the use of miscellaneous topical agents, growth factors, and skin equivalents for the treatment of pressure ulcers. Dermatol Surg 21:145-148
38. Falanga V (2004) The chronic wound: impaired healing and solutions in the context of wound bed preparation. Blood Cells Mol Dis 32:88-94
39. Robson MC, Mustoe TA, Hunt TK (1998) The future of recombinant growth factors in wound healing. Am J Surg 176 [Suppl 2A]: 80S-82S
40. Falanga V (1993) Growth factors and wound healing. Dermatol Clin 11:667-675
41. Lewis M, Pearson A, Ward C (2003) Pressure ulcer prevention and treatment: transforming research findings into consensus based clinical guidelines. Int J Nurs Pract 9:92-102
42. Strauss EA, Margolis DJ (1996) Malnutrition in patients with pressure ulcers: morbidity, mortality, and clinically practical assessments. Adv Wound Care 9:37-40
43. Bennett NT, Schultz GS (1993) Growth factors and wound healing: Part II. Role in normal and chronic wound healing. Am J Surg 166:74-81
44. Thomas DR (2003) The promise of topical growth factors in healing pressure ulcers. Ann Intern Med 139:694-695
45. Evans CA, Hagelstein SM, Ivins NM (2000) Current challenges in wound care management: an overview. Br J Community Nurs 5:332, 334-336, 338-339
46. Steed DL (1995) Clinical evaluation of recombinant human platelet derived growth factor for the treatment of lower extremity diabetic ulcers. The diabetic ulcer study group. J Vase Surg 21:71-78
47. Smiell JM, Wieman TJ, Steed DL, Perry BH, Sampson AR, Schwab BH (1999) Efficacy and safety of becaplermin (recombinant human platelet-derived growth factor-BB) in patients with nonhealing, lower extremity diabetic ulcers: a combined analysis of four randomized studies. Wound Repair Regen 7:335-346
48. Mulder GD (2001) Diabetic foot ulcers: old problems - new technologies. Nephrol Dial Transplant 16:695-698
49. Robson MC, Phillips LG, Thomason A, Robson LE, Pierce GF (1992) Plateletderived growth factor BB for the treatment of chronic pressure ulcers. Lancet 339:23-25
50. Robson MC, Phillips LG, Thomason A, Altrock BW, Pence PC, Heggers JP, Johnston AF, McHugh TP, Anthony MS, Robson LE, et al. (1992) Recombinant human platelet-derived growth factor-BB for the treatment of chronic pressure ulcers. Ann Plast Surg 29:193-201
51. Rees RS, Robson MC, Smiell JM, Perry BH (1999) Becaplermin gel in the treatment of pressure ulcers: a phase II randomized, double-blind, placebocontrolled study. Wound Repair Regen 7:141-147
52. Pierce GF, Tarpley JE, Allman RM, Goode PS, Serdar CM, Morris B, Mustoe TA, Vandeberg J (1994) Tissue repair processes in healing chronic pressure ulcers treated with recombinant platelet-derived growth factor BB. Am J Pathol 145:1399-1410
53. Robson MC, Abdullah A, Burns BF, Philips LG, Garrison L, Cowan W, Hill D, Vandeberg J, Robson LE, Scheeler S (1994) Safety and effect of topical recombinant human interleukin-1/β in the management of pressure sores. Wound Repair Regen 2:177-181
54. Robson MC, Phillips LG, Lawrence WT, Bishop JB, Youngerman JS, Hayward PG, Broemeling LD, Heggers JP (1992) The safety and effect of topically applied recombinant basic fibroblast growth factor on the healing of chronic pressure sores. Ann Surg 216:401-406
55. Hirshberg J, Coleman J, Marchant B, Rees RS (2001) TGF-beta3 in the treatment of pressure ulcers: a preliminary report. Adv Skin Wound Care 14:91-95
56. Landi F, Aloe L, Russo A, Cesari M, Onder G, Bonini S, Carbonin PU, Bernabei R (2003) Topical treatment of pressure ulcers with nerve growth factor: a randomized clinical trial. Ann Intern Med 139:635-641
57. Robson MC (1991) Growth factors as wound healing agents. Curr Opin Biotechnol 2:863-867
58. Cross SE, Roberts MS (1999) Defining a model to predict the distribution of topically applied growth factors and other solutes in excisional full-thickness wounds. J Invest Dermatol 112:36-41
59. Diegelmann RF (2003) Excessive neutrophils characterize chronic pressure ulcers. Wound Repair Regen 11:490-495
60. Edwards JV, Yager DR, Cohen IK, Diegelmann RF, Montante S, Bertoniere N, Bopp AF (2001) Modified cotton gauze dressings that selectively absorb neutrophil elastase activity in solution. Wound Repair Regen 9:50-58
61. Jimenez PA, Jimenez SE (2004) Tissue and cellular approaches to wound repair. Am J Surg 187:56S-64S
62. Jones JE, Nelson EA (2000) Skin grafting for venous leg ulcers. Cochrane Database Syst Rev: CD001737
63. Nerem RM (1992) Tissue engineering in the USA. Med Biol Eng Comput 30: CE8-12
64. Lee KH (2000) Tissue-engineered human skin substitutes: development and clinical application. Yonsei Med J 41:774-779
65. Rheinwald JG, Green H (1975) Serial cultivation of strains of human epidermal keratinocytes: the formation of keratinizing colonies from single cells. Cell 6:331-343
66. Ramos-E-Silva M, Ribeiro De Castro MC (2002) New dressings, including tissue-engineered living skin. Clin Dermatol 20:715-723
67. Bello YM, Falabella AF, Eaglstein WH (2001) Tissue-engineered skin. Current status in wound healing. Am J Clin Dermatol 2:305-313
68. Green H, Kehinde O, Thomas J (1979) Growth of cultured human epidermal cells into multiple epithelia suitable for grafting. Proc Natl Acad Sci USA 76:5665-5668
69. O'Connor NE, Mulliken JB, Bank-Schlegel S, et al. (1981) Grafting of bruns with cultured epithelium prepared from autologous epidermal cells. Lancet 1:75-78
70. Gallico GG 3rd, O'Connor NE, Compton CC, Kehinde O, Green H (1984) Permanent coverage of large burn wounds with autologous cultured human epithelium. N Engl J Med 311:448-451
71. Hefton JM, Caldwell D, Biozes DG, Balin AK, Carter DM (1986) Grafting of skin ulcers with cultured autologous epidermal cells. J Am Acad Dermatol 14:399-405
72. Phillips TJ, Pachas W (1994) Clinical trial of cultured autologous keratinocyte grafts in the treatment of long-standing pressure ulcers. Wounds 6:113-119
73. Mansbridge J (2002) Tissue-engineered skin substitutes. Expert Opin Biol Ther 2:25-34
74. Sefton MV, Woodhouse KA (1998) Tissue engineering. J Cutan Med Surg 3 [Suppl 1]: 18-23
75. Phillips TJ (1999) Tissue-engineered skin: an alternative to split-thickness skin grafts? Arch Dermatol 135:977-978
76. Prunieras M, Regnier M, Woodley D (1983) Methods for cultivation of keratinocytes with an air-liquid interface. J Invest Dermatol 81 [Suppl 1]: 28s-33s
77. Ponec M, Boelsma E, Weerheim A, Mulder A, Bouwstra J, Mommaas M (2000) Lipid and ultrastructural characterization of reconstructed skin models. Int J Pharm 203:211-225
78. Ponec M, Boelsma E, Gibbs S, Mommaas M (2002) Characterization of reconstructed skin models. Skin Pharmacol Appl Skin Physiol 15 [Suppl 1]: 4-17
79. Coquette A, Berna N, Vandenbosch A, Rosdy M, De Wever B, Poumay Y (2003) Analysis of interleukin-1 alpha (IL-lalpha) and interleukin-8 (IL-8) expression and release in in vitro reconstructed human epidermis for the prediction of in vivo skin irritation and/or sensitization. Toxicol In Vitro 17:311-321
80. Faller C, Bracher M (2002) Reconstructed skin kits: reproducibility of cutaneous irritancy testing. Skin Pharmacol Appl Skin Physiol 15 [Suppl 1]: 74-91
81. Gibbs S, Vietsch H, Meier U, Ponec M (2002) Effect of skin barrier competence on SLS and water-induced IL-lalpha expression. Exp Dermatol 11:217-223
82. Eaglstein WH, Falanga V (1998) Tissue engineering for skin: an update. J Am Acad Dermatol 39:1007-1010
83. Mansbridge JN, Liu K, Pinney RE, Patch R, Ratcliffe A, Naughton GK (1999) Growth factors secreted by fibroblasts: role in healing diabetic foot ulcers. Diabetes Obes Metab 1:265-279
84. Pinney E, Liu K, Sheeman B, Mansbridge J (2000) J. Human three-dimensional fibroblast cultures express angiogenic activity. J Cell Physiol 183:74-82
85. Liu K, Yang Y, Mansbridge J (2000) Comparison of the stress response to cryopreservation in monolayer and three-dimensional human fibroblast cultures: stress proteins, MAP kinases, and growth factor gene expression. Tissue Eng 6:539-554
86. Phillips TJ (1998) New skin for old: developments in biological skin substitutes. Arch Dermatol 134:344-349
87. Brem H, Balledux J, Bloom T, Kerstein MD, Hollier L (2000) Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: a new paradigm in wound healing. Arch Surg 135:627-634
88. Falanga V, Sabolinski M (1999) A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen 7:201-207
89. Falanga V (1999) How to use Apligraf to treat venous ulcers. Skin Aging 25:30-36
90. Pham HT, Rosenblum BI, Lyons TE, et al. (1999) Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective, randomized, clinical trial. Wounds 11:79-86
91. Ponec M, Wauben-Penris PJ, Burger A, Kempenaar J, Bodde HE (1990) Nitroglycerin and sucrose permeability as quality markers for reconstructed human epidermis. Skin Pharmacol 3:126-135
92. Ponec M, Weerheim A, Kempenaar J, Mulder A, Gooris GS, Bouwstra J, Mommaas AM (1997) The formation of competent barrier lipids in reconstructed human epidermis requires the presence of vitamin C. J Invest Dermatol 109:348-355
93. Ponec M, Gibbs S, Pilgram G, Boelsma E, Koerten H, Bouwstra J, Mommaas M (2001) Barrier function in reconstructed epidermis and its resemblance to native human skin. Skin Pharmacol Appl Skin Physiol 14 [Suppl 1]: 63-71
94. Medalie DA, Eming SA, Collins ME, Tompkins RG, Yarmush ML, Morgan JR (1997) Differences in dermal analogs influence subsequent pigmentation, epidermal differentiation, basement membrane, and rete ridge formation of transplanted composite skin grafts. Transplantation 64:454-465
95. Guo M, Grinnell F (1989) Basement membrane and human epidermal differentiation in vitro. J Invest Dermatol 93:372-378
96. Andreadis ST (2004) Gene transfer to epidermal stem cells: implications for tissue engineering. Expert Opin Biol Ther 4:783-800
97. Eming SA, Medalie DA, Tompkins RG, Yarmush ML, Morgan JR (1998) Genetically modified human keratinocytes overexpressing PDGF-A enhance the performance of a composite skin graft. Hum Gene Ther 9:529-539
98. Eming SA, Lee J, Snow RG, Tompkins RG, Yarmush ML, Morgan JR (1995) Genetically modified human epidermis overexpressing PDGF-A directs the development of a cellular and vascular connective tissue stroma when transplanted to athymic mice - implications for the use of genetically modified keratinocytes to modulate dermal regeneration. J Invest Dermatol 105:756-763
99. Supp DM, Supp AP, Bell SM, Boyce ST (2000) Enhanced vascularization of cultured skin substitutes genetically modified to overexpress vascular endothelial growth factor. J Invest Dermatol 114:5-13
100. Supp DM, Boyce ST (2002) Overexpression of vascular endothelial growth factor accelerates early vascularization and improves healing of genetically modified cultured skin substitutes. J Burn Care Rehabil 23:10-20
101. Liechty KW, Nesbit M, Herlyn M, Radu A, Adzick NS, Crombleholme TM (1999) Adenoviral-mediated overexpression of platelet-derived growth factor-B corrects ischemic impaired wound healing. J Invest Dermatol 113:375-383
102. Liechty KW, Sablich TJ, Adzick NS, Crombleholme TM (1999) Recombinant adenoviral mediated gene transfer in ischemic impaired wound healing. Wound Repair Regen 7:148-153
103. Andree C, Swain WF, Page CP, Macklin MD, Slama J, Hatzis D, Eriksson E (1994) In vivo transfer and expression of a human epidermal growth factor gene accelerates wound repair. Proc Natl Acad Sci USA 91:12188-12192
104. Benn SI, Whitsitt JS, Broadley KN, Nanney LB, Perkins D, He L, Patel M, Morgan JR, Swain WF, Davidson JM (1996) Particle-mediated gene transfer with transforming growth factor-betal cDNAs enhances wound repair in rat skin. J Clin Invest 98:2894-2902
105. Eming SA, Whitsitt JS, He L, Krieg T, Morgan JR, Davidson JM (1999) Particle-mediated gene transfer of PDGF isoforms promotes wound repair. J Invest Dermatol 112:297-302
106. Eriksson E, Yao F, Svensjo T, Winkler T, Slama J, Macklin MD, Andree C, McGregor M, Hinshaw V, Swain WF (1998) In vivo gene transfer to skin and wound by microseeding. J Surg Res 78:85-91
107. Sun L, Xu L, Chang H, Henry FA, Miller RM, Harmon JM, Nielsen TB (1997) Transfection with aFGF cDNA improves wound healing. J Invest Dermatol 108:313-318
108. Kim HM, Choi DH, Lee YM (1998) Inhibition of wound-induced expression of transforming growth factor-beta 1 mRNA by its antisense oligonucleotides. Pharmacol Res 37:289-293
109. Thierry AR, Rahman A, Dritschilo A (1992) Liposomal delivery as a new approach to transport antisense oligonucleotides. In Erickson R, Izant JG, editors. Gene regulation: biology of antisense RNA and DNA. Raven Press, New York, pp 147-161
110. Choi BM, Kwak HJ, Jun. CD, Park SD, Kim KY, Kim HR, Chung HT (1996) Control of scarring in adult wounds using antisense transforming growth factor-beta 1 oligodeoxynucleotides. Immunol Cell Biol 74:144-150